Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus and treated with linezolid or vancomycin: A secondary, post-hoc analysis based on a Phase 4 clinical trial study

Journal of Medical Economics

Volumn 19, Issue 1, 2016, Pages 53-62

  Wan, Yin ^a   Li, Qiang ^b   Chen, Yixi ^c   Haider, Seema ^c   Liu, Sizhu ^a   Gao, Xin ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c PFIZER INC   (United States)

Author keywords

China; Costeffectiveness analysis; Economics; Methicillin resistant Staphylococcus aureus; Nosocomial pneumonia; Renal failure

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CHINESE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; CHINA; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS INFECTION; DOUBLE BLIND PROCEDURE; ECONOMICS; HEALTH SERVICE; MIDDLE AGED; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; UTILIZATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHINA; COMORBIDITY; COST-BENEFIT ANALYSIS; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; HEALTH SERVICES; HUMANS; LINEZOLID; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MODELS, ECONOMETRIC; PNEUMONIA, BACTERIAL; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84954364855     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1088448     Document Type: Article

References (31)

1. Goetghebeur M, Landry PA, Han D, et al. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007; 18: 27-34
2. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Contr & Hosp Epidemiol 2000; 21: 510-15
3. Hu F, Zhu D, Wang F. CHINET surveillance of bacterial resistance in China. China J Infect Chemother 2011; 12: 321-9
4. Liu YN, Cao B, Wang H, et al. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberculosis Respir Dis 2012; 35: 739-46
5. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008; 36 (4 Suppl): S216-23
6. Sun W, Chen H, Liu Y, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrobial Agents Chemother 2009; 53: 3642-9
7. Hu J, Ma XX, Tian Y, et al. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive staphylococcus aureus clinical isolates in Northeast China. PloS One 2013; 8: e73300
8. Zyvox® [package insert]. New York, NY: Pfizer Inc. 2012
9. Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199: 804-16
10. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrobial Chemother 2007; 60: 1361-9
11. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189: 425-8
12. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis Offl Publ Infect Dis Soc Am 2012; 54: 621-9
13. Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative w: acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care (London, England) 2004; 8: R204-12
14. Efron B. An introduction to the Bootstrap. New York: Chapman and Hall, 1993
15. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-15
16. Notice of medicine and pharmaceutical market order rectification. Available from: http://www.sdpc.gov.cn/zfdj/jggg/zyfw/t20060602-128839.htm. Accessed October 3 2015
17. A notification regarding the promoting of the reform in drug price at country level public hospital. Available from: http://www.ndrc.gov.cn/zcfb/zcfbtz/2012tz/t20120919-505765.htm. Accessed October 3 2015
18. Niederman MS CJ SC, Wan Y, Gao X, et al. Incidence of renal failure and associated economic burden among patients with nosocomial pneumonia caused by methicillin resistant staphylococcus aureus (MRSA-NP) treated with linezolid or vancomycin: a secondary analysis of a multi-center randomized double-blind clinical trial. San Deigo, CA: IDWeek, 2012
19. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32: 137-43
20. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection 2009; 37: 123-32
21. Cao Ja, Su Tb, Li Xb. Acute kidney injury caused by anti-infective drugs. Adverse Drug React 2010;12:325-8
22. Che M, Yan Y, Zhang Y, et al. [Analysis of drug-induced acute renal failure in Shanghai]. Zhonghua Yi Xue Za Zhi 2009; 89: 744-9
23. Du B, Chen DC, Liu DW. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections]. Chin Critical Care Med 2003; 15: 32-4
24. Fang Y, Ding X, Zhong Y, et al. Acute kidney injury in a Chinese hospitalized population. Blood Purif 2010; 30: 120-6
25. Julián-Mauro JC, Cuervo J, Rebollo P, et al. Employment status and indirect costs in patients with renal failure: differences between different modalities of renal replacement therapy. Off Publ Spanish Soc Nephrol 2013; 33: 333-41
26. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management & quest. Kid Int 2005; 68: 1808-14
27. Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Contr 2008; 36 (4 Suppl): S93-100
28. Zhuo C, Xu YC, Xiao SN, et al. Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China. Int J Antimicrob Agents 2013; 41: 578-81
29. Zhang X, Hu Q, Yuan W, et al. First report of a sequence type 239 vancomycin-intermediate Staphylococcus aureus isolate in Mainland China. Diagn Microbiol Infect Dis 2013; 77: 64-8
30. Grau S, Rubio-Terres C. Pharmacoeconomics of linezolid. Exp Opin Pharmacother 2008; 9: 987-1000
31. Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Therapeut 2003; 10: 264-74